Eyeworld

DISCOVER THE POWER OF GEL Indications and Usage • LOTEMAX ® GEL is a corticosteroid indicated for the treatment of post-operative infl ammation and pain following ocular surgery Important Risk Information about LOTEMAX ® GEL • LOTEMAX ® GEL is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures • Intraocular pressure (IOP) increase—Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fi elds of vision. If this product is used for 10 days or longer, IOP should be monitored • Cataracts—Use of corticosteroids may result in posterior subcapsular cataract formation • Delayed healing—Use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation and occurrence of perforations in those with diseases causing corneal and scleral thinning. The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnifi cation • Bacterial infections—Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infection. In acute purulent conditions, steroids may mask infection or enhance existing infections • Viral infections—Use of corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and exacerbate the severity of many viral infections of the eye (including herpes simplex) • Fungal infections—Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use • Contact lens wear—Patients should not wear contact lenses when using LOTEMAX ® GEL • The most common ocular adverse drug reactions were anterior chamber infl ammation (5%), eye pain (2%) and foreign body sensation (2%) LOTEMAX ® GEL–UNIQUE FORMULATION DESIGNED TO CONTROL INFLAMMATION MUCOADHESIVE TECHNOLOGY— Engineered to adhere to the ocular surface 1-3 DOSE UNIFORMITY— No shaking required to resuspend drug 1,4,5 LOW PRESERVATIVE AND TWO KNOWN MOISTURIZERS 1,2,4,6 PROVEN EFFICACY AND ESTABLISHED SAFETY 1,2,7 Please see brief summary of full prescribing information on adjacent page. References: 1. LOTEMAX GEL Prescribing Information, September 2012. 2. Fong R, Leitritz M, Siou-Mermet R, Erb T. Loteprednol etabonate gel 0.5% for postoperative pain and infl ammation after cataract surgery: results of a multicenter trial. Clin Ophthalmol. 2012;6:1113-1124. 3. Shaikh R, Singh TRR, Garland MJ, Woolfson AD, Donnelly RF. Mucoadhesive drug delivery systems. J Pharm Bioallied Sci. 2011;3(1):89-100. 4. Data on fi le, Bausch & Lomb Incorporated. 5. Coffey MJ, Davio SR. Viscoelastic and sedimentation characterization of loteprednol etabonate ophthalmic gel, 0.5%. Poster presented at: Association for Research in Vision and Ophthalmology (ARVO); May 6-10, 2012; Fort Lauderdale, FL. Poster #6283/D1143. 6. Lotemax Prescribing Information, April 2006. 7. Rajpal RK, Roel l, Siou-Mermet R, Erb T. Effi cacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular infl ammation and pain after cataract surgery. J Cataract Refract Surg. 2013;39:158-167. ®/ TM are trademarks of Bausch & Lomb Incorporated or its affi liates. ©2013 Bausch & Lomb Incorporated. US/LGX/13/0049 [4/13]

• Cover